Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dose-escalation”

6,710 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 6,710 results

Early research (Phase 1)Study completedNCT01859117
What this trial is testing

Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers

Who this might be right for
Peripheral Arterial DiseaseDiabetic Foot Ulcer
Celularity Incorporated 15
Post-approval studies (Phase 4)Looking for participantsNCT06821191
What this trial is testing

Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study

Who this might be right for
Coronary Artery Disease
University of Florida 78
Early research (Phase 1)Looking for participantsNCT06708897
What this trial is testing

Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

Who this might be right for
CLL / SLLCLL (Chronic Lymphocytic Leukemia)SLL (Small Lymphocytic Lymphoma)+2 more
Lomond Therapeutics Holdings, Inc. 84
Early research (Phase 1)Looking for participantsNCT04245397
What this trial is testing

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Syntrix Biosystems, Inc. 151
Testing effectiveness (Phase 2)Study completedNCT00040846
What this trial is testing

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+97 more
Fred Hutchinson Cancer Center 60
Testing effectiveness (Phase 2)Study completedNCT02061761
What this trial is testing

Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Who this might be right for
Hematologic Neoplasms
Bristol-Myers Squibb 106
Testing effectiveness (Phase 2)Study completedNCT04645069
What this trial is testing

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced/Metastatic Solid Tumors
Adagene Inc 58
Early research (Phase 1)Study completedNCT00874042
What this trial is testing

Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 74
Early research (Phase 1)Study completedNCT00733642
What this trial is testing

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Who this might be right for
Alzheimer's Disease
Pfizer 15
Early research (Phase 1)Study completedNCT02259842
What this trial is testing

Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers

Who this might be right for
Healthy
Boehringer Ingelheim 63
Early research (Phase 1)Active Not RecruitingNCT06125197
What this trial is testing

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
TILT Biotherapeutics Ltd. 22
Early research (Phase 1)Looking for participantsNCT06660420
What this trial is testing

Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

Who this might be right for
Phase 1Recurrent MelanomaRefractory Melanoma
M.D. Anderson Cancer Center 39
Early research (Phase 1)Ended earlyNCT02252796
What this trial is testing

Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
West Virginia University 1
Early research (Phase 1)UnknownNCT05675462
What this trial is testing

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Fudan University 25
Early research (Phase 1)Study completedNCT00047762
What this trial is testing

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Genentech, Inc.
Early research (Phase 1)Looking for participantsNCT06088888
What this trial is testing

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

Who this might be right for
Chronic Myelogenous Leukemia
Shenzhen TargetRx Co., Ltd. 90
Early research (Phase 1)Active Not RecruitingNCT04594642
What this trial is testing

AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Who this might be right for
B-cell Non Hodgkin LymphomaDiffuse Large B Cell LymphomaHigh-grade B-cell Lymphoma+1 more
AstraZeneca 226
Early research (Phase 1)Study completedNCT00698243
What this trial is testing

Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Any Solid Tumor or Lymphoma
Astellas Pharma Inc 128
Early research (Phase 1)Study completedNCT01364415
What this trial is testing

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Who this might be right for
Neuroendocrine Tumors
Novartis Pharmaceuticals 29
Testing effectiveness (Phase 2)Study completedNCT05828108
What this trial is testing

Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

Who this might be right for
Steroid-refractory Diamond-Blackfan Anemia (DBA)
National Heart, Lung, and Blood Institute (NHLBI) 15
Next Page